View profile

The week in Italian startups - Issue #68

The week in Italian startups - Issue #68
By Niccolò Sanarico • Issue #68 • View online
I am Niccolò from Primo Ventures, welcome back to my digest of what happened in the Italian startup ecosystem.
In this issue: summer rounds for Entando, Resalis Therapeutics, Enerbrain, YOLO, Seedata, and HT Material Science; Helbiz completes its listing on the NASDAQ.
Enjoy the reading, see you on the other side,

The Money
  • I talked about Helbiz and its listing on the NASDAQ before. It was supposed to merge with the GreenVision SPAC and to raise further capital via a PIPE.
  • Well, the listing was finally closed on the 13th of August, with a total raise of $24.5m, including $21m from the PIPE.
  • But the listing was bumpy: first, soon after completing the deal, the company received a delisting notice, related to confusion about floating enough capital on the NASDAQ.
  • Secondly (and probable cause of the notice above), the investors in the GreenVision SPAC were apparently not satisfied with the merger, as 95% of the capital originally raised by the SPAC was actually refunded before completing the deal.
  • Nonetheless, Helbiz is now the first publicly listed e-scooter sharing startup.
A bumpy road
A bumpy road
Jobs in Italian startups
Ending Notes
We are back on Clubhouse to discuss the summer news (and we are also back to our schedule, every Monday at 6:30 pm CEST). In case you miss the live discussion, you can subscribe to the podcast on Spotify.
Happy to be here with you again. Have a great week!
Did you enjoy this issue?
Niccolò Sanarico

The week in Italian startups is a weekly collection of the most interesting news in the Italian startup ecosystem, with a focus on funding rounds, milestones, major partnerships, and innovation news. The weekly email will be in your inbox on Monday morning(-ish).

By subscribing, you will only receive one weekly email, nothing else, nothing more.

This newsletter is supported by the Italian Tech Alliance (

In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue